Compare MakeMyTrip Ltd (MMYT) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Stryker Corporation — how do they compare? MakeMyTrip Ltd trades at $44.57 (market cap $4.09B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 26× MakeMyTrip Ltd's market cap, and Stryker Corporation pays a 1.27% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Stryker Corporation for 21 Days on average.
| MMYT | SYK | |
|---|---|---|
Market Cap | $4.09B | $106.24B |
Volume | 1,828,010 | 2,982,001 |
Sector | Consumer Cyclical | Health |
52-Week High | $94.43 | $388.35 |
52-Week Low | $36.30 | $269.75 |
Typical Hold Time | 12 Days | 21 Days |
Enterprise Value | $4.75B | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMYT trades at $44.33, up 2.12% today, but technical indicators signal a bearish trend. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, though net income margin remains thin at 3.23%. Analyst consensus is strongly bullish with a $77.00 price target, but institutional selling and a projected decline in 2026 cash flow pose concerns.
The stock presents a high-risk, high-reward opportunity. Strong analyst support and a potential Indian listing offer upside, but bearish technicals, earnings volatility, and rising debt-to-asset ratios in 2026 highlight significant risks. Investors should weigh the optimistic price targets against fundamental pressures and market sentiment.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
